Scott Breidbart Biography and Net Worth

Director of Aclarion

Dr. Scott Breidbart has an extensive background in health care delivery. He is an advisor to Redesign Health and a consultant for Stellar Health. Redesign Health is a mission-driven innovation platform that launches transformative healthcare companies. Stellar Health is a healthcare technology company focused on enabling success across the value-based care continuum by bridging the incentive gap between providers and payors.

Dr. Breidbart has an over 20 year history in managed care, most recently as the Chief Medical Officer of Affinity Health Plans. He has also served as Chief Medical Officer of Solera Health, the Chief Clinical Officer of Emblem Health, the Chief Medical Officer of Empire BlueCross BlueShield, and has held various roles in medical management for HealthNet. Dr. Breidbart practiced pediatric endocrinology for ten years on the faculty of New York Medical College. He is Board Certified in Pediatrics and Pediatric Endocrinology and is licensed to practice medicine in NY. He holds a BA in Mathematics from Yale, an MD from Columbia, and an MBA from Pace University.

What is Scott Breidbart's net worth?: The estimated net worth of Scott Breidbart is at least $13.42 thousand as of May 12th, 2026. Dr. Breidbart owns 5,664 shares of Aclarion stock worth more than $13,424 as of October 8th. This net worth approximation does not reflect any other investments that Dr. Breidbart may own. Learn More about Scott Breidbart's net worth.
How do I contact Scott Breidbart?: The corporate mailing address for Dr. Breidbart and other Aclarion executives is 8181 Arista Place, Ste 100, Broomfield, CO, 80021. Aclarion can also be reached via phone at 833-275-2266. Learn More on Scott Breidbart's contact information.
Has Scott Breidbart been buying or selling shares of Aclarion?: Scott Breidbart has not been actively trading shares of Aclarion within the last three months. Most recently, on Tuesday, May 12th, Scott Breidbart bought 5,664 shares of Aclarion stock. The stock was acquired at an average cost of $3.18 per share, with a total value of $18,011.52. Following the completion of the transaction, the director now directly owns 5,664 shares of the company's stock, valued at $18,011.52. Learn More on Scott Breidbart's trading history.
Who are Aclarion's active insiders?: Aclarion's insider roster includes Ryan Bond (Chief Strategy Officer), Scott Breidbart (Director), Gregory Gould (CFO), Gregory Gould (CFO), David Neal (Director), Brent Ness (CEO), Brent Ness (Chief Executive Officer, President, and Director), and Amanda Williams (Director). Learn More on Aclarion's active insiders.
Are insiders buying or selling shares of Aclarion?: During the last twelve months, Aclarion insiders bought shares 11 times. They purchased a total of 67,888 shares worth more than $176,647.43. The most recent insider tranaction occured on August, 17th when Director Amanda M Williams bought 5,857 shares worth more than $15,989.61. Insiders at Aclarion own 0.0% of the company. Learn More about insider trades at Aclarion.
Information on this page was last updated on 8/17/2026.

Scott Breidbart Insider Trading History at Aclarion

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/12/2026	Buy	5,664	$3.18	$18,011.52	5,664

Scott Breidbart Buying and Selling Activity at Aclarion

Aclarion Company Overview

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Today's Range

Now: $2.35

$2.32

$2.41

50 Day Range

MA: $2.46

$2.02

$2.94

2 Week Range

Now: $2.35

$1.95

$12.03

Volume

21,449 shs

Average Volume

325,158 shs

Market Capitalization

$6.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2